Director at Tectonic Therapeutic (TECX) awarded 20,400 stock options at $30.78

Q: What did Tectonic Therapeutic (TECX) disclose about Nader Francois in this Form 4?

Tectonic Therapeutic reported that director Nader Francois received a grant of stock options for 20,400 shares of common stock at an exercise price of $30.78 per share, expiring on March 31, 2036 , held as a direct derivative position.

Q: How many Tectonic Therapeutic (TECX) shares are covered by the new option grant?

The new option grant to director Nader Francois covers 20,400 shares of Tectonic Therapeutic common stock. These are derivative securities that give him the right to buy common shares at a fixed exercise price if and when they vest and are exercised.

Q: What is the exercise price and expiration date of the TECX stock options granted?

The stock options granted to Nader Francois have an exercise price of $30.78 per share . They carry an expiration date of March 31, 2036 , giving a long-dated right to purchase Tectonic Therapeutic common stock once the options have vested.

Q: What is the vesting schedule for Nader Francois’s Tectonic Therapeutic (TECX) options?

One third of the option grant vests on April 1, 2027 , with the remaining shares vesting in 24 equal monthly installments thereafter. Vesting is conditioned on continuous service to Tectonic Therapeutic through each applicable vesting date.

Q: Is this TECX Form 4 transaction a market purchase or sale of shares?

No, the Form 4 reports a grant of stock options , not a market trade. The transaction code is A , described as a grant, award, or other acquisition, giving Nader Francois the right to buy 20,400 shares at a future time, subject to vesting.

Q: How many derivative securities does Nader Francois hold after this TECX option grant?

After the reported transaction, the Form 4 shows 20,400 derivative securities held directly by Nader Francois . These correspond to stock options on Tectonic Therapeutic common stock from the newly granted award described in the filing.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Tectonic Therapeutic, Inc. director Nader Francois received a grant of stock options covering 20,400 shares of common stock. The options have an exercise price of $30.78 per share and expire on March 31, 2036.

One third of the option vests on April 1, 2027, with the remaining two thirds vesting in 24 equal monthly installments, as long as Francois continues to provide service through each vesting date. Following this grant, the filing shows 20,400 derivative securities held directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Nader Francois

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	20,400	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 20,400 shares (Direct)

Footnotes (1)

[object Object]

Key Figures

Option grant size: 20,400 shares Exercise price: $30.78 per share Expiration date: March 31, 2036 +3 more

6 metrics

Option grant size 20,400 shares Stock Option (Right to Buy) granted to director Nader Francois

Exercise price $30.78 per share Conversion or exercise price of granted stock options

Expiration date March 31, 2036 Expiration of the stock option grant

Post-grant derivative holdings 20,400 derivative securities Total derivative securities following transaction

Initial vesting date April 1, 2027 One third of option grant vests on this date

Remaining vesting pattern 24 monthly installments Balance vests in equal monthly tranches after April 1, 2027

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, exercise price, vesting, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

exercise price financial

"conversion_or_exercise_price: "30.7800""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"shares subject to the option shall vest on April 1, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: "2036-03-31T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Form 4 Insider Transactions: What Each Field Means →

04/03/2026 - 04:23 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nader Francois

(Last)

(First)

(Middle)

C/O TECTONIC THERAPEUTIC, INC.

490 ARSENAL WAY, SUITE 200

(Street)

WATERTOWN

MASSACHUSETTS

02472

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tectonic Therapeutic, Inc. [ TECX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$30.78	04/01/2026		A		20,400		⁽¹⁾	03/31/2036	Common Stock	20,400	$0	20,400	D

Explanation of Responses:

1. One Third (1/3) of the shares subject to the option shall vest on April 1, 2027, and the balance shall vest in 24 equal monthly installments thereafter, subject in each case, to the Reporting Person providing continuous service to the Issuer through each applicable vesting date.

	/s/ Daniel Lochner, Attorney-in-Fact	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Tectonic Therapeutic (TECX) disclose about Nader Francois in this Form 4?

Tectonic Therapeutic reported that director Nader Francois received a grant of stock options for 20,400 shares of common stock at an exercise price of $30.78 per share, expiring on March 31, 2036, held as a direct derivative position.

How many Tectonic Therapeutic (TECX) shares are covered by the new option grant?

The new option grant to director Nader Francois covers 20,400 shares of Tectonic Therapeutic common stock. These are derivative securities that give him the right to buy common shares at a fixed exercise price if and when they vest and are exercised.

What is the exercise price and expiration date of the TECX stock options granted?

The stock options granted to Nader Francois have an exercise price of $30.78 per share. They carry an expiration date of March 31, 2036, giving a long-dated right to purchase Tectonic Therapeutic common stock once the options have vested.

What is the vesting schedule for Nader Francois’s Tectonic Therapeutic (TECX) options?

One third of the option grant vests on April 1, 2027, with the remaining shares vesting in 24 equal monthly installments thereafter. Vesting is conditioned on continuous service to Tectonic Therapeutic through each applicable vesting date.

Is this TECX Form 4 transaction a market purchase or sale of shares?

No, the Form 4 reports a grant of stock options, not a market trade. The transaction code is A, described as a grant, award, or other acquisition, giving Nader Francois the right to buy 20,400 shares at a future time, subject to vesting.

How many derivative securities does Nader Francois hold after this TECX option grant?

After the reported transaction, the Form 4 shows 20,400 derivative securities held directly by Nader Francois. These correspond to stock options on Tectonic Therapeutic common stock from the newly granted award described in the filing.